ATOS | tickerfilter.com

Fundamental analysis

41%

Profitability 35%

Dept financing 20%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

8.97%

1 Month

13.65%

3 Months

866.83%

6 Months

477.23%

1 Year

815.80%

2 Year

325.55%

Key data

Stock price

$5.83

P/E Ratio

N/A

DAY RANGE

$5.66 - $5.94

EPS

-$1.46

52 WEEK RANGE

$0.53 - $7.56

52 WEEK CHANGE

$815.80

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

8.611 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

2.52

PUBLIC FLOAT

AVERAGE 10 VOLUME

$52,703

AVERAGE 30 VOLUME

$69,241

Company detail

CEO: Steven C. Quay
Region: US
Website: atossatherapeutics.com
Employees: 8
IPO year: 2012

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Atossa Therapeutics, Inc. focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxefen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized patients.

ATOS - ATOSSA THERAPEUTICS, INC.